Every 8-K that The Cooper Companies, Inc. (COO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow COO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COO filings page.
Cooper Companies, Inc. (COO) reported fiscal third quarter 2026 results with modest top-line growth but strong profitability and cash generation. Revenue rose 1% year over year to $1.066 billion, including 1% organic growth. GAAP diluted EPS jumped to $2.24 from $0.49, largely driven by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination tied to a 2021 intellectual property transfer.
On an adjusted basis, non-GAAP diluted EPS was $1.15, up 4%, and non-GAAP operating margin improved 30 bps to 26%, reflecting expense management and productivity initiatives. Free cash flow grew 66% to $273.0 million, with operating cash flow of $341.7 million and capital expenditures of $68.7 million. CooperVision revenue was flat at $717.0 million as the company proactively reduced U.S. channel inventory, while CooperSurgical revenue increased 2% to $349.2 million, with fertility revenue up 5% organically.
CooperCompanies completed its strategic review and the Board unanimously decided to retain CooperSurgical after determining that offers received did not meet its view of shareholder value. As part of a revised capital allocation strategy, the company repurchased $339.1 million (about 4.9 million shares) in the quarter and expanded its share repurchase authorization from $2 billion to $3 billion, leaving approximately $1.5 billion available. Updated fiscal 2026 guidance calls for total revenue of $4.229–$4.252 billion (organic growth 2–3%) and non-GAAP diluted EPS of $4.51–$4.55, with continued emphasis on free cash flow exceeding $2.2 billion over fiscal 2026–2028.
CooperCompanies reported fiscal second quarter 2026 results showing solid underlying growth but a large litigation impact. Revenue was $1.082 billion, up 8% year over year and 5% organically, with both CooperVision and CooperSurgical growing 8%.
GAAP diluted EPS was a loss of $(0.40) versus a profit of $0.44 a year ago, driven by a $271.6 million net pre-tax charge related to product-liability litigation from CooperSurgical’s December 2023 embryo culture media recall. This included $324.1 million of accrued litigation liabilities, partly offset by $52.5 million of expected insurance recoveries.
On a non-GAAP basis, diluted EPS rose 26% to $1.21 and operating margin increased to 27%, reflecting disciplined cost management and benefits from prior reorganization. Free cash flow was $96.4 million, and the company repurchased $13.1 million of stock. Management updated 2026 guidance, targeting total revenue of $4.285–$4.321 billion and non-GAAP EPS of $4.58–$4.66, and reaffirmed a long-term free cash flow objective exceeding $2.2 billion for fiscal 2026–2028.
CooperCompanies is expanding its Board of Directors from nine to ten members and has appointed Paul Keel as an independent director, effective July 1, 2026. He will also join the Board’s Audit Committee on that date.
Keel is currently President and CEO of Envista Holdings Corporation and previously served as CEO of Smiths Group plc, following 16 years in leadership roles at 3M. He will receive director compensation consistent with other non-employee directors. The company highlights its global medical device focus through CooperVision and CooperSurgical, serving more than fifty million people annually in over 130 countries.
The Cooper Companies, Inc. reported results of its 2026 Annual Meeting of Stockholders held on April 7, 2026. Stockholders elected all nine director nominees, ratified KPMG LLP as independent auditor for the fiscal year ending October 31, 2026, and approved executive compensation on an advisory basis.
CooperCompanies reported a solid fiscal first quarter 2026, with revenue of $1.024 billion, up 6% from a year earlier and 3% organically. Growth was led by CooperVision, where revenue rose 8% to $695.1 million, while CooperSurgical revenue increased 3% to $329.0 million.
GAAP diluted EPS grew to $0.66, up 27%, and non-GAAP diluted EPS rose to $1.10, up 20%, as operating margin improved to 21% on a GAAP basis and 27% on a non-GAAP basis. Free cash flow was $158.7 million, supporting $92.5 million of share repurchases. The company raised its fiscal 2026 outlook, guiding total revenue to $4.306–$4.346 billion, non-GAAP EPS to $4.58–$4.66, and free cash flow to $600–$625 million.
The Cooper Companies, Inc. amended its debt agreements to adjust terms on its term loan and revolving credit facilities. The company extended the maturity of $950 million of term loans to February 3, 2031, while keeping the maturity date for the remaining $550 million of term loans unchanged.
The amendment also removes the prior credit spread adjustment and raises the cap on incremental term loans to the greater of $1.365 billion and 100% of consolidated EBITDA. Pricing on the term loans can now be based either on the company’s non-credit enhanced, senior unsecured long-term debt ratings or on its consolidated net indebtedness to consolidated EBITDA ratio.
A related amendment to the revolving credit agreement aligns its provisions with the revised term loan agreement, including the removal of credit spread adjustments.
On December 9, 2025, The Cooper Companies, Inc. assigned its Executive Vice President, Chief Financial Officer and Treasurer, Brian G. Andrews, the additional role of principal accounting officer, taking over that responsibility from Agostino Ricupati.
Mr. Ricupati will continue serving as the company’s Senior Vice President, Tax. The company states there are no special arrangements, family relationships, related-party transactions or compensation changes associated with Mr. Andrews’ assumption of the principal accounting officer role.
The Cooper Companies, Inc. furnished a current report to disclose that it issued a press release announcing its results for the fiscal third quarter ended July 31, 2025.
The press release, dated August 27, 2025, is provided as Exhibit 99.1 and is incorporated by reference into this report, but is designated as “furnished” rather than “filed” under securities laws. The company also includes an Inline XBRL cover page data file as Exhibit 104.1, and the report is signed by President and Chief Executive Officer Albert G. White III.